Jean‐pierre Devogelaer

Jean‐pierre Devogelaer's AcademicInfluence.com Rankings

Philosophy

#9742

World Rank

#13345

Historical Rank

Logic

#6702

World Rank

#8247

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Jean‐pierre Devogelaer's Degrees

Doctorate Medicine Université libre de Bruxelles
PhD Medical Sciences Université libre de Bruxelles

Why Is Jean‐pierre Devogelaer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jean‐pierre Devogelaer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Ten years’ experience with alendronate for osteoporosis in postmenopausal women* (2004) (1275)
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. (2005) (1080)
Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. (1988) (898)
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. (2002) (868)
Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid‐Induced Osteoporosis in Men and Women: A Randomized Trial (2000) (531)
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. (2009) (436)
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial (2009) (349)
Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity (1995) (315)
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. (2000) (229)
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. (2001) (198)
Effects of Dairy Products Consumption on Health: Benefits and Beliefs—A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (2015) (196)
Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. (2004) (185)
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. (1996) (183)
Management of Glucocorticoid-Induced Osteoporosis (2012) (166)
Intravertebral vacuum cleft: changes in content after supine positioning. (1993) (165)
Genome-wide association identifies three new susceptibility loci for Paget's disease of bone (2011) (160)
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club (2009) (155)
Risedronate Increases Bone Density and Reduces Vertebral Fracture Risk Within One Year in Men on Corticosteroid Therapy (2001) (153)
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club (2005) (152)
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial (2013) (150)
Long‐Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate (2006) (147)
Primary Prevention of Glucocorticoid‐Induced Osteoporosis with Intravenous Pamidronate and Calcium: A Prospective Controlled 1‐Year Study Comparing a Single Infusion, an Infusion Given Once Every 3 Months, and Calcium Alone (2001) (144)
Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. (1993) (142)
Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients (2000) (141)
Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. (2006) (131)
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. (2007) (130)
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. (2004) (130)
Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. (1999) (128)
Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. (2000) (127)
Dietary chicory inulin increases whole-body bone mineral density in growing male rats. (2002) (125)
Inhomogeneity of human vertebral cancellous bone: systematic density and structure patterns inside the vertebral body. (2001) (125)
Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. (1995) (124)
Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intermittent Intravenous Pamidronate: A Randomized Trial (1997) (119)
Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section. (1996) (119)
Beneficial effects of creatine supplementation in dystrophic patients (2003) (118)
Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review (2003) (117)
Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. (2009) (115)
Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single- and dual-photon absorptiometry and with quantitative computed tomography. (1992) (115)
Effects of strontium ranelate on spinal osteoarthritis progression (2007) (111)
ETIDRONATE AND THE RISK OF FRACTURES (1985) (110)
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis (2011) (109)
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club (2010) (108)
Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club (2011) (104)
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club (2005) (103)
Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta (2004) (103)
Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. (1987) (101)
18F-Fluoride PET for Monitoring Therapeutic Response in Paget’s Disease of Bone (2005) (101)
Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. (2000) (101)
Side-effects of intravenous cyclophosphamide pulse therapy (1997) (101)
Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study. (1992) (100)
Safety and Efficacy of a Novel Salmon Calcitonin (sCT) Technology‐Based Oral Formulation in Healthy Postmenopausal Women: Acute and 3‐Month Effects on Biomarkers of Bone Turnover (2004) (98)
Strontium Ranelate Reduces the Risk of Vertebral Fractures in Patients With Osteopenia (2006) (95)
Trabecular and cortical bone loss in systemic lupus erythematosus. (1996) (94)
BPS804 Anti‐Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial (2017) (94)
Urban tropospheric ozone increases the prevalence of vitamin D deficiency among Belgian postmenopausal women with outdoor activities during summer. (2008) (91)
Fluoride effects on bone formation and mineralization are influenced by genetics. (2008) (90)
Effects of Calcitonin on Subchondral Trabecular Bone Changes and on Osteoarthritic Cartilage Lesions After Acute Anterior Cruciate Ligament Deficiency (2004) (88)
Novel LRP5 Missense Mutation in a Patient With a High Bone Mass Phenotype Results in Decreased DKK1‐Mediated Inhibition of Wnt Signaling* (2007) (87)
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. (2005) (82)
Loading and Skeletal Development and Maintenance (2010) (82)
Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage (2000) (81)
Pagets-disease of Bone (1981) (81)
Scintigraphy using a technetium 99m-labelled anti-E-selectin Fab fragment in rheumatoid arthritis. (2002) (80)
A FRAX® model for the assessment of fracture probability in Belgium (2009) (80)
Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. (2005) (78)
Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. (2004) (78)
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications (2012) (75)
Renal expression of parvalbumin is critical for NaCl handling and response to diuretics (2007) (75)
The Effects of MK‐0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture (2004) (75)
Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging. (1999) (73)
Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis (2007) (72)
Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis (2015) (70)
Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis (2008) (68)
The effect of low dosage glucocorticoids on bone mass in rheumatoid arthritis: a cross-sectional and a longitudinal study using single photon absorptiometry. (1984) (66)
Identification of Sex‐Specific Associations Between Polymorphisms of the Osteoprotegerin Gene, TNFRSF11B, and Paget's Disease of Bone (2007) (65)
LHRH ANALOGUES AND BONE LOSS (1987) (64)
Cross-link profile of bone collagen correlates with structural organization of trabeculae. (2002) (64)
Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. (1998) (59)
Goal-directed treatment of osteoporosis in Europe (2014) (58)
Bone density and markers of bone remodeling in type 1 male diabetic patients. (2006) (58)
Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation (2002) (58)
Evaluation of the Role of the SQSTM1 Gene in Sporadic Belgian Patients with Paget’s Disease (2004) (58)
The majority of the genetic risk for Paget’s disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes (2010) (57)
Background for studies on the treatment of male osteoporosis: state of the art (2000) (56)
Treatment of osteoporosis in men. (2004) (56)
Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. (2003) (55)
The genetic influence on bone susceptibility to fluoride. (2006) (55)
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. (2010) (54)
Hematological changes in anorexia nervosa are correlated with total body fat mass depletion. (1997) (53)
Inulin and fructo-oligosaccharides differ in their ability to enhance the density of cancellous and cortical bone in the axial and peripheral skeleton of growing rats. (2006) (52)
Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest. (1999) (52)
Treatment of bone diseases with bisphosphonates, excluding osteoporosis (2000) (51)
The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club (2016) (51)
CALCITONIN OR DIPHOSPHONATES FOR OSTEOLYTIC PAGET'S DISEASE? (1980) (51)
Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture (2016) (51)
Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: A position paper of the european foundation for osteoporosis and bone disease (2005) (51)
IL‐12 inhibits in vitro immunoglobulin production by human lupus peripheral blood mononuclear cells (PBMC) (1997) (50)
A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment (2004) (49)
Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis (2010) (48)
DIPHOSPHONATES AND INHIBITION OF BONE MINERALISATION (1982) (48)
Dissociation of parathyroid hormone bioactivity and immunoreactivity in pseudohypoparathyroidism type I. (1981) (47)
(18)F-fluoride PET for monitoring therapeutic response in Paget's disease of bone. (2005) (47)
Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in a sample of white women from Belgium. (2001) (47)
Intravenous zoledronic acid in postmenopausal women with low bone mineral density (2003) (46)
Effect of a stemless femoral implant for total hip arthroplasty on the bone mineral density of the proximal femur. A prospective longitudinal study. (1997) (46)
Health Technology Assessment in Osteoporosis (2013) (45)
Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. (2015) (45)
Paget's disease of bone. (1982) (44)
Erosive azotemic osteoarthropathy: possible role of amyloidosis. (1985) (43)
Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone (2010) (41)
RELATIVE VITAMIN D DEFICIENCY IN PAGET'S DISEASE (1981) (40)
Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. (2010) (40)
Automated computerized radiogrammetry of the second metacarpal and its correlation with absorptiometry of the forearm and spine (1994) (40)
Rationale for the potential use of calcitonin in osteoarthritis. (2005) (39)
Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. (2006) (39)
Spontaneous rupture of the distal iliopsoas tendon: clinical and imaging findings, with anatomic correlations (2005) (37)
Long-Term Effects on Bone Mineral Density of Different Therapeutic Schemes for Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma during Childhood (2010) (37)
Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results? (1999) (35)
Founder Effect in Different European Countries for the Recurrent P392L SQSTM1 Mutation in Paget’s Disease of Bone (2008) (35)
Color Doppler sonography of the temporal arteries in giant cell arteritis and polymyalgia rheumatica. (1997) (35)
Treatment of the vertebral crush fracture syndrome with enteric‐coated sodium fluoride tablets and calcium supplements (1990) (34)
Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients (2005) (34)
The arthritis of hemochromatosis. A review of 25 cases with special reference to chondrocalcinosis, and a comparison with patients with primary hyperparathyroidism and controls (1986) (33)
Indications for a genetic association of a VCP polymorphism with the pathogenesis of sporadic Paget's disease of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms. (2011) (33)
New modes of administration of salmon calcitonin in Paget's disease. Nasal spray and suppository. (1987) (31)
Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity. (1992) (31)
Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty (2015) (31)
Comparative Effect of Nimesulide and Ibuprofen on the Urinary Levels of Collagen Type II C-Telopeptide Degradation Products and on the Serum Levels of Hyaluronan and Matrix Metalloproteinases-3 and -13 in Patients with Flare-Up of Osteoarthritis (2005) (30)
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis (2012) (30)
Patient-specific microarchitecture of vertebral cancellous bone: a peripheral quantitative computed tomographic and histological study. (2002) (30)
Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatments in Belgium (2003) (30)
Inhibition of cytochemical bioactivity of parathyroid hormone by plasma in pseudohypoparathyroidism type I. (1982) (30)
Erratum to: Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis (2017) (29)
Pustulotic arthroosteitis and chronic recurrent multifocal osteomyelitis in children. Report of three cases. (1988) (29)
Increase in the incidence of hip fractures and of the ratio of trochanteric to cervical hip fractures in Belgium (1988) (27)
The Action of the Main Therapeutic Regimes On Pagets-disease of Bone, With a Note On the Effect of Vitamin-d Deficiency (1980) (27)
Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club (2008) (27)
New uses of bisphosphonates: osteogenesis imperfecta. (2002) (26)
PSEUDOHYPOPARATHYROIDISM: INHERITANCE AND EXPRESSION OF DEFICIENT RECEPTOR‐CYCLASE COUPLING PROTEIN ACTIVITY (1983) (25)
Modern Therapy for Paget’s Disease of Bone (2002) (25)
Hypocalcaemia and chronic alcohol intoxication: Transient hypoparathyroidism secondary to magnesium deficiency (1996) (25)
Is there a place for bone turnover markers in the assessment of osteoporosis and its treatment? (2011) (24)
Raloxifene reduces fractures in postmenopausal women with osteoporosis. (2006) (23)
Lactose intolerance, calcium intake, and osteopenia (1991) (23)
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2016) (23)
[Articular amyloidosis, femoral neck fracture and chronic periodic hemodialysis]. (1985) (23)
Occurrence of a painful stress fracture of the femoral neck simultaneously with six other asymptomatic localizations in a runner. (1994) (21)
Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta. (2019) (21)
D-penicillamine induced crescentic glomerulonephritis: report and review of the literature. (1987) (21)
Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women. (1998) (21)
Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis (2002) (20)
Do Estrogens Effectively Prevent Osteoporosis-Related Fractures? (2000) (20)
Articular chondrocalcinosis in seropositive rheumatoid arthritis. Comparison with a control group. (1987) (20)
[Evaluation of corticosteroid replacement therapy and its effect on bones in Addison's disease]. (2000) (19)
Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis (2015) (18)
Remission Over 3 Years in Patients with Paget Disease of Bone Treated with a Single Intravenous Infusion of 5 mg Zoledronic Acid (2013) (17)
Recommendations for the Registration of Agents Used in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (1996) (17)
Effect of nimesulide on the serum levels of hyaluronan and stromelysin‐1 in patients with osteoarthritis: a pilot study (2004) (17)
Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone (2019) (16)
Vertebral cancellous bone turn-over: microcallus and bridges in backscatter electron microscopy. (2005) (16)
Fluoride treatment for osteoporosis (1990) (16)
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. (2013) (16)
Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice (2020) (16)
The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES) (2010) (15)
Reflex sympathetic dystrophy syndrome: an unusual mode of presentation of osteomalacia. (1986) (15)
Clinical use of bisphosphonates (1996) (15)
Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men (2010) (15)
Endocrinological status of postmenopausal osteoporosis. (1986) (14)
Teriparatide versus alendronate for treatment of glucocorticoid-induced osteoporosis: 36-month results (2008) (14)
[Roentgenologic Evaluation of the Action of the Diphosphonate Ehdp and of Combined Therapy (ehdp and Calcitonin) in Pagets-disease of Bone] (1980) (14)
Influence of the menopausal state on the effect of low-dose glucocorticoid on bone mass in rheumatoid arthritis patients. (1986) (13)
Clinical Significance of Antiproteinase 3 Antibody Positivity in cANCA-Positive Patients (1999) (13)
Oral alendronate induces progressive increases in bone mass of the spine, hip and total body over 3 years in postmenopausal women with osteoporosis (1996) (13)
Dual energy x-ray absorptiometry-based assessment of male patients using standardized bone density values and a national reference database. (2007) (12)
Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone. (1997) (12)
Therapy and the 1990s - Osteoporosis (1993) (11)
Products of Cartilage Metabolism (2006) (11)
Does orthodontic loading influence bone mineral density around titanium miniplates? An experimental study in dogs. (2010) (11)
SUPPRESSION OF PARATHYROID HORMONE INHIBITORY ACTIVITY OF PLASMA IN PSEUDOHYPOPARATHYROIDISM TYPE I BY IV CALCIUM (1986) (10)
A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis (1998) (10)
Osteogenesis Imperfecta (2006) (10)
Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta : Results of a Randomized Phase 2 a Trial (2017) (10)
Incidentaloma, glucocorticoid excess and low bone mineral density: a coincidence? (2001) (10)
Bioavailability of enteric‐coated sodium fluoride tablets as affected by the administration of calcium supplements at different time intervals (1990) (10)
Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue (1994) (10)
Non-hormonal treatment of osteoporosis (1983) (9)
Fluoride therapy of type I osteoporosis (1995) (9)
Separation of inhibitory activity from biologically active parathyroid hormone in patients with pseudohypoparathyroidism type I. (1986) (9)
A review of the effects of tibolone on the skeleton (2004) (8)
Guidelines for clinical studies assessing the efficacy of drugs for the management of acute low back pain. (2003) (8)
Infliximab therapy leads to clinical and radiographic benefits in early rheumatoid arthritis patients receiving optimum methotrexate dose (2004) (8)
Antacid-induced osteomalacia (2005) (8)
Tacrolimus and low‐dose steroid immunosuppression preserves bone mass after renal transplantation (2002) (8)
Use of pamidronate in chronic and acute bone loss conditions. (1997) (8)
Intra-articular calcification in progressive systemic sclerosis (1986) (7)
A rare case of bronchial stenosis in Wegener's granulomatosis. Dramatic response to intravenous cyclophosphamide and oral cotrimoxazole. (1992) (7)
Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort (2019) (7)
Zoledronic acid for treatment of Paget's disease of bone (2007) (7)
CALCITONIN OR MITHRAMYCIN FOR PAGET'S DISEASE (1980) (7)
[Loss of digital tissues and carpal canal syndrome. Apropos of 3 cases]. (1986) (7)
Bone mineral density in posttransplantation patients: effects of physical activity. (2000) (7)
[Involvement of the shoulder in rheumatoid arthritis]. (1995) (6)
Recommendations for the Registration of Drugs Intended for Use in the Treatment of Male Osteoporosis (1999) (6)
Hypercalcaemia in acute adrenal insufficiency. A case report. (1990) (6)
Avascular bone necrosis in SLE patients is associated with glucocorticoid use but not with antiphospholipid antibodies. (1996) (5)
Ipriflavone in the Treatment of Postmenopausal Osteoporosis (2017) (5)
Intravenous zoledronic acid (ZOL) compared to IV pamidronate (PAM) in children with severe osteogenesis imperfecta (OI) (2008) (5)
Prevention and treatment of postmenopausal osteoporosis national consensus of the “belgian bone club”, November 1996 (1997) (5)
1,25-Dihydroxyvitamin D-related hypercalcemia in lymphoma: Two case reports (1990) (5)
Bone Turnover Markers and Glucocorticoid Treatments (2016) (5)
Ocular neuromyotonia in a case of Paget's disease of bone (1997) (5)
Genetic variation in the TNFRSF11A (RANK) gene contributes to the risk to develop sporadic Paget's disease of bone (2009) (5)
Strontium ranelate: The first anti-osteoporotic agent to reduce the risk of vertebral fracture in patients with lumbar osteopenia (2004) (5)
Risedronate is effective and well tolerated in treating corticosteroid-induced osteoporosis. (1998) (5)
Paradoxical immunologic effects of 2-CdA therapy: comment on the article by Davis et al. (1998) (5)
Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse (2021) (5)
Follow up of DXA bone mineral density measurement in severe and refractory rheumatoid arthritis (RA) treated with Infliximab (IFX) (2004) (5)
A Study of the Accuracy of 3 Dpa, and One Dual-energy X-ray Bone Densitometers (1990) (5)
Evaluation of the simple calculated osteoporosis risk estimation in a sample of Caucasian women from Belgium (2001) (5)
How do you know who needs prevention or treatment? (1997) (5)
Validation of pQCT for human vertebral bone samples density measurement (2000) (4)
Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget’s Disease of Bone and Modifies the Age of Onset (2019) (4)
A novel LRP5 mutation in a patient with increased bone mass results in reduced DKK1-inhibition (2006) (4)
Osteomalacia due to chemotherapy-induced Fanconi syndrome in an adult patient. (2005) (4)
Osteophytes and osteoarthritis progression. Effects of nonsteroidal antiinflammatory drugs. (1999) (4)
Neuromuscular disorders associated with D-penicillamine treatment for rheumatoid arthritis. (1985) (4)
Cost-effectiveness analysis of Aclasta in Paget's disease of bone in Belgium (2005) (4)
Sclerostin neutralizing monoclonal antibody decreases significantly the number of pelvic fractures and improves dramatically the size and interconnectivity of lumbar trabecular bone in oim/oim mice (2012) (4)
A case of cholestatic hepatitis associated with D-penicillamine therapy for rheumatoid arthritis. (1985) (4)
Long-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 years (2011) (4)
Does peripheral quantitative computed tomography ignore tissue density of cancellous bone? (2002) (4)
COMPARISON OF 1,25 (OH)2D3 LEVELS AFTER THE ADMINISTRATION OF CALCITRIOL AND ALFACALCIDOL (1991) (4)
Long-lasting effect of pamidronate on bone metabolism in osteoporosis after stopping therapy. (2000) (4)
Bone mineral density in Addison's disease. (1987) (3)
Safety of combination of methotrexate (MTX) and infliximab (IFX) in a large Belgian observational patient cohort with refractory rheumatoid arthritis. (2002) (3)
Do estrogens effectively prevent osteoporosis-related fractures? The Group for the Respect of Ethics and Excellence in Science. (2000) (3)
Comparison between the bone mass measurement obtained by computerized radiogrammetry and dual- or single photon absorptiometry (1992) (3)
Effects of Dairy Products Consumption on Health: Benefits and Beliefs—A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (2015) (3)
Biochemical and Molecular Actions of Nutrients Research Communication (2002) (3)
Apparent versus true acquired resistance to pamidronate in Paget's disease of bone (1992) (3)
Glomerular thrombosis: an unusual cause of renal failure in systemic lupus erythematosus. (1998) (3)
Ocular Neuromyotonia in a Case of Paget??s Disease of Bone (1998) (3)
Systemic lupus erythematosus and concomitant malignant lymphoma. A case report. (1987) (3)
Role of Vitamin-d Supplementation in Cholestatic Cirrhosis in Rat (1995) (3)
[Evaluation of glucocorticoid replacement therapy and of their effects on bone mineral density in Addison's disease] (2000) (3)
Postnatal growth defect in mice upon persistent Hoxa2 expression in the chondrogenic cell lineage. (2012) (3)
Points to consider for the development of new indications for hormone replacement therapies and estrogen-like molecules. Department of Urogynaecology, King's College Hospital, London. (1998) (3)
Effect of a Nasal Spray of Salmon-calcitonin in Normal Subjects and in Patients With Pagets-disease of Bone (1986) (3)
Long term follow up of untreated primary hyperparathyroidism. (1985) (2)
Ipriflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women (2000) (2)
Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in Caucasian women with postmenopausal osteoporosis (2004) (2)
Alternative Modes of Administration of Salmon Calcitonin in Paget's Disease of Bone (1991) (2)
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation. (2004) (2)
The effect of infliximab therapy on the prevention of new erosions in patients with early rheumatoid arthritis. (2004) (2)
Long-term treatment of postmenopausal osteoporotic women with strontium ranelate : results at 10 years (2011) (2)
A single dose of zoledronic acid 5 mg achieves more sustained biochemical remission versus daily 30mg risedronate in patients with Paget's disease (2006) (2)
101 CALCITONIN PREVENTS THE LOSS OF CONNECTIVITY AND COMPLEXIITY OF TRABECULAR SUBCHONDRAL BONE IN EARLY STAGES OF CANINE OSTEOARTHRITIS (2010) (2)
Pseudohypoparathyroidism. A case report, with studies on the pathogenesis of the condition. (1984) (2)
A double-blind, placebo-controlled study to determine the effects of risedronate on bone loss in glucocorticoid-treated rheumatoid arthritis patients (2006) (2)
Colour Doppler sonography of the temporal arteries in giant cell arteritis and polymyalgia rheumatica. (1996) (1)
Vitamin D deficiency in elderly people. (1991) (1)
The Separation of Biologically-active Parathyroid-hormone From Inhibitory Activity in Plasma From Patients With Pseudohypoparathyroidism Type-i (1986) (1)
A single infusion of zoledronic acid 5 mg is significantly more effective than daily oral risedronate 5 mg in increasing bone mineral density of the lumbar spine, hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis (2008) (1)
Biologically Inactive Parathyroid-hormone (pth) in Pseudohypoparathyroidism Type-i (php-i) (1980) (1)
Comparative double-blind multicenter study of the efficacy of tiludronate and etidronate in Paget's disease of bone (1995) (1)
Bone-mineral Density in Addisons-disease (1987) (1)
Effect of Zoledronic Acid (Single 5-mg Infusion) on Lumbar Spine Bone Mineral Density Versus Oral Risedronate (5 mg/day) Over 1 Year in Subgroups of Patients Receiving Glucocorticoid Therapy. (2008) (1)
CHANGES IN BRAIN WATER IN SYSTEMIC LUPUS ERYTHEMATOSUS (1986) (1)
Osteogenesis imperfecta and short stature: effect of sclerostin antibody treatment in oim/oim mice (2013) (1)
Cutaneous mucinosis associated with multiple frozen joints and bony heterotopic deposits around the hips (1986) (1)
Prevention of glucocorticoid-induced osteoporosis (GC-OP) with intravenous pamidronate and calcium: A prospective controlled one-year study comparing a single infusion, a 3-monthly therapy and calcium alone (2000) (1)
Dissociation between bone formation and bone resorption evidenced by changes in biochemical markers of bone turnover in patients treated with strontium ranelate (2007) (1)
Bisphosphonates and glucocorticoid osteoporosis in premenopausal women: Results of a randomized controlled trial comparing zoledronic acid with risedronate (2010) (1)
Deflazacort in giant cell arteritis. (2002) (1)
Design for an ipriflavone multicenter European fracture study (2009) (1)
Effect of a single 5 mg infusion of zoledronic acid on bone turnover markars vs. oral risedronate (5 mg/day) over 1 year in patients with glucocorticoid-induced osteoporosis (2008) (1)
[Loss of digital substance in rheumatic diseases. Apropos of 43 cases]. (1987) (1)
Evaluation of proposals of Belgian Social Security Institute for reimbursement of bone densitometry tests. Toward a costeffective strategy for osteoporosis screening? (2004) (1)
Zoledronic acid safety and efficacy over 5 years in postmenopausal osteoporosis (2006) (1)
Tiludronate and etidronate in Paget's disease of bone: a comparative prospective double-blind multicenter study (1994) (1)
Effect of Glucocorticoids On Bone - a Radiologic and Absorptiometric Approach (1982) (1)
Home based exercise for osteoarthritis (2004) (1)
Osteopenia, bone fragility and reflex sympathetic dystrophy syndrome in a man with ureterosigmoidostomy (2005) (1)
Rapid and sustained anti-fracture efficacy of strontium ranelate in postmenopausal osteoporosis (2002) (1)
Healing of Ehdp-induced Osteomalacia By Calcitonin (1985) (1)
Risedronate reduces the risk of new vertebral fractures in 1 year in postmenopausal women on corticosteroid therapy (2001) (1)
Bone mineral density (BMD) after transplantation: Effect of physical activity (2001) (1)
[The Synovial-fluid - Interest of its Study As a Diagnostic-aid in Rheumatic Disorders] (1980) (1)
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (health outcomes and reduced incidence with zoledronic acid once yearly trial): A multicentre, double-blind, double-dummy, randomized controlled trial (2009) (1)
Fluoride effects on bone formation, mineralization and mechanical properties are influenced by genetics (2008) (1)
[Treatment of postmenopausal osteoporosis in 2004]. (2004) (1)
[Postmenopausal osteoporosis in women]. (1999) (1)
Bisphosphonate therapy for the treatment of postmenopausal osteoporosis (2005) (1)
Lactose intolerance (LI) predisposes to reduced perimenopausal BMD. (1997) (1)
D-penicillamine-induced Crescentic Glomerulonephritis (cg) (1985) (1)
No role for Polymorphisms in the gene encoding RANKL in the development of sporadic Paget's disease of bone in contrast to some OPG polymorphisms (2007) (1)
Spinal stenosis and Paget's disease of bone (2000) (0)
Relation of Osteopenia to Glucocorticoid Replacement Therapy in Addison Disease (1994) (0)
PAPER 10: SECONDARY FRACTURE PREVENTION IN ORTHOPAEDIC WARDS IN BELGIUM: THE FORWARD PROGRAM (2010) (0)
Long-term safety of infliximab (INX) with methotrexate (MTX) in a large belgian observational patient cohort with severe, refractory rheumatoid arthritis (RA) (2006) (0)
SAT0341 Strontium Ranelate Improves Osteoarthritis Symptoms Compared to Placebo in Patients with Knee OA - The Sekoia Study (2013) (0)
[Physio-pathology of pseudohypoparathyroidism (author's transl)]. (1979) (0)
Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice (2020) (0)
Inhaled corticosteroids effects on bone in asthmatic and COPD patients: what is the evidence? (2002) (0)
Uncoupling of bone formation and resorption with a novel oral formulation of salmon calcitonin in postmenopausal women (2003) (0)
Efficacy of long-term treatment of Paget's disease with tiludronate 400 mg/day. (1996) (0)
Health Technology Assessment in Osteoporosis (2013) (0)
Management of Glucocorticoid-Induced Osteoporosis (2012) (0)
The simple calculated ostoporosis risk estimation (SCORE) does not allow to identify Belgian women with a high risk of osteoporosis (2000) (0)
Low risk of fractures in long-term treatment of Paget's disease with tiludronate. (1996) (0)
[Metabolic investigation of a population of institutionalized epileptics (author's transl)]. (1979) (0)
[Involutional osteoporosis in women: therapeutic strategy. Recommendations of the Belgian Bone Club]. (2000) (0)
Toward an efficient strategy for osteoporosis screening : diagnostic accuracy and cost effectiveness of the proposals of the Belgian social security institute (2001) (0)
Predictive value of whole body bisphosphonate retention on lumbar BMD after a two years period of bisphosphonate therapy (2003) (0)
[Hyperprebetalipoproteinemia and synovial xanthomatosis]. (1985) (0)
Utility audit of Belgian DXA centers (2008) (0)
Increase in femoral neck bone mineral density is associated with decrease in hip fracture incidence during treatment with strontium ranelate (2006) (0)
18F-fluoride positron emission tomography: Preliminary assessment of therapy in Paget's disease of bone (2003) (0)
Multicenter long study on reproducibility of dual photon absorptiometry (1987) (0)
Calcitonin partly counteracts the subchondral bone remodelling underlying experimental osteoarthritis: Morphometric data from PQCT scanning (2007) (0)
Metabolic action on bone of anticonvulsant therapy in institutionalized patients suffering from epilepsy (2000) (0)
Estimation from early changes of serum procollagen type 1 aminoterminal propeptide of the lumbar BMD gain after 2 years in children suffering from severe osteogenesis imperfecta (2005) (0)
POS2: INTEREST OF THE SIMPLE CALCULATED OSTEOPOROSIS RISK ESTIMATION (SCORE) TOOL FOR A MORE RATIONAL USE OF BONE DENSITOMETRY (2000) (0)
Timing of DAS28 in infliximab therapy: reply (2005) (0)
Erratum to: Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture (2017) (0)
Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget’s Disease of Bone and Modifies the Age of Onset (2019) (0)
Lack of significant toxicity of a daily supplementation of 1 g elemental calcium and 880 IU vitamin D in postmenopausal women. (2001) (0)
A Panel-Based Sequencing Analysis of Patients with Paget’s Disease of Bone Suggests Enrichment of Rare Genetic Variation in regulators of NF-κB Signaling and Supports the Importance of the 7q33 Locus (2021) (0)
[Septic arthritis due to common bacteria in the adult]. (1986) (0)
Prevention of Glucocorticoid Induced Osteoporosis - 2 Treatment Options Assessed By Dual Photon-absorptiometry (1988) (0)
Validation of the critera proposed by the Belgian social security institute for reimbursement of bone mineral density : a study in a sample of 4727 ambulatory subjects (2000) (0)
Effects of strontium ranelate on radiographic spinal osteoarthritis progression (2007) (0)
[Study of a population of HLA-B27 positive blood donors (author's transl)]. (1979) (0)
FRAX(r) and the assessment of fracture probability in men and women from Belgium. (2009) (0)
[A FRAX model for the assessment of fracture probability in Belgium]. (2009) (0)
Corrigendum to "Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronate" [Bone 50 (2012) 289-295] (2012) (0)
Intranasal calcitonin and plasma calcium concentrations. (1985) (0)
POS3: THE SIMPLE CALCULATED OSTEOPOROSIS RISK ESTIMATION (SCORE) DOES NOT ALLOW IDENTIFICATION OF BELGIAN WOMEN WITH A HIGH RISK OF OSTEOPOROSIS (2000) (0)
Remanent effect of pamidronate on bone metabolism in osteoporosis (2006) (0)
Evolution of early Paget's disease in SQSTM1 mutation carriers: baseline analysis of the ZiPP study (2019) (0)
Belgian bone specialists are eagerly looking to the availability of new medications in osteoporosis (2006) (0)
Osteoporosis in males is chiefly a secondary condition (2006) (0)
[Soft-tissue Destruction of Digits in Rheumatic Disorders - a Study of 43 Cases] (1987) (0)
Effects of Strontium Ranelate On Knee Osteoarthritis Pain: A Responder Analysis (2012) (0)
Lactase Deficiency - a Role for Lumbar Bone Mass in Males (1992) (0)
Recent trends in the increase of hip fractures in Belgium (1992) (0)
Involvement of the chondro-osseous junction in canine experimental osteoarthritis. Effect of calcitonin (2008) (0)
Ninth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis – ECCEO 9 – IOF (2009) (0)
Effect of various types of inulin and oligofructose from chicory on bone (2004) (0)
Secondary fracture prevention measures in orthopedic wards in Belgium (2007) (0)
Is the subchondral plate involved in osteoarthritis development? Histological analysis of canine tibiae after anterior cruciate ligament section and calciton in treatment (2007) (0)
Interest of a simple pre-screening test for optimizing the cost/benefit value of bone densitometry (1999) (0)
Zoledronate in the prevention of Paget(cid:146)s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1 mediated Paget(cid:146)s disease of bone (2019) (0)
363 EVIDENCE THAT THE NEUTRAL ACTIVE HYALURONIDASE PH-20 CONTRIBUTES TO THE BREAKDOWN OF CARTILAGE MATRIX IN HUMAN KNEE OSTEOARTHRITIS (2007) (0)
Effect of a aingle i.v. infusion of zoledronic acid on bone turnover markers versus oral risedronate in patients with glucocorticoid-induced osteoporosis (2009) (0)
Evaluation of the proposals of the Belgian social security institute for the reimbursement of bone densitometry, toward a cost effective strategy for osteoporosis screening (2001) (0)
Poster 43: Effect of Intravenous Zoledronic Acid on Lumbar Spine Bone Mineral Density Compared to Oral Risedronate in Subgroups of Patients Receiving Glucocorticoid Therapy (2009) (0)
Osteoporosis and lactose intolerance. (1996) (0)
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2015): ESCEO Symposia Abstracts (2015) (0)
Effects of a single 5 mg infusion of zoledronic acid and oral risedronate (5 mg/day) on bone remodeling over one year in patients with glucocorticoid-induced osteoporosis (2008) (0)
Spinal stenosis in Paget's disease of bone. (2000) (0)
Severe trabecular and cortical bone loss in systemic lupus erythematosus (SLE): The respective roles of disease and corticosteroids (CS) (2006) (0)
Titanium orthodontic miniplates in dogs: Anchorage evaluation with bone mineral density measurement (2007) (0)
Ninth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis – ECCEO 9 – IOF (2009) (0)
[Semiology and classification of the different types of osteopenia: osteoporosis, osteomalacia and tumoral osteolysis (author's transl)]. (1973) (0)
[Comparison of 1,25-(oh)2d3 Levels With the Histomorphometric Measurements of Osteomalacia in Patients With Disordered Vitamin-d Metabolism] (1980) (0)
Do we have to revise the plasma values of 25OHD in normal elderly subjects (2004) (0)
OP-10. Imaging of endothelial activation using 99Tcm-anti-E-selectin Fab in rheumatoid arthritis (1997) (0)
MRI bone marrow changes in SLE: Correlation with glucocorticoid intake and avascular osteonecrosis. (1997) (0)
Skeletal growth deficit as result of antagonism between Hoxa2 expression and chondrocyte differentiation: Morphological and densitometric study (2007) (0)
Bisphosphonate-associated atypical femoral fracture, effect of teriparatide (2014) (0)
DXA-based assessment of male patients using standardized bone density values and a national reference database (2006) (0)
Bone-mineral Density in Kidney-transplant Recipients (1992) (0)
Relations between increase in femoral neck bone mineral density and decrease in hip fracture incidence during treatment with strontium ranelate (2006) (0)
Meta-analysis of the effects of inhaled corticosteroids on bone in asthmatic and COPD patients (2002) (0)
Bone mineral density in severe and refractory rheumatoid arthritis patients treated with infliximab (2003) (0)
Osteoporosis assessment and treatment after hip or forearm fracture: a Belgian experience (2007) (0)
[How to evaluate osteoporosis: bone densitometry and biochemical tests]. (1999) (0)
[Sarcomatous transformation in Paget's disease of bone. Apropos of 3 case reports]. (1985) (0)
Remission Over 3 Years in Patients with Paget Disease of Bone Treated with a Single Intravenous Infusion of 5 mg Zoledronic Acid (2013) (0)
Fibroblast growth factor 23 and PTH are strong determinants of the bone mineral density changes occuring within the first post-renal transplantation year (2008) (0)
Abstracts of the 33rd European Symposium on Calcified Tissues (2006) (0)
A rare case of primary skeletal muscle lymphoma: The value of octreotide scintigraphy (1995) (0)
Can systematic daily supplementation of 1G elemental calcium and 880 IU vitamin D in any ambulatory postmenopausal women be safely administered (2002) (0)
Timing of DAS28 in infliximab therapy. Authors' reply (2005) (0)
Evaluation of bone mineral density in a population of pre-pubertal children with JIA (2009) (0)
[Study of a population of HLA-B27-positive blood donors]. (1979) (0)
Testing for hypoparathyroidism. (1979) (0)
Effectiveness of zoledronic acid in the prevention and treatment of glucocorticoid-induced osteoporosis in men and premenopausal women (2010) (0)
Inhaled corticosteroids and risk of osteoporosis in asthma ‐ reply (2005) (0)
Source of body weight loss induced by gastroplasty in obese subjects (2002) (0)
Chapter 21 – The Pathogenesis of Glucocorticoid-Induced Bone Loss (2006) (0)
Poster 42: Effect of a Single Intravenous Infusion of Zoledronic Acid on Bone Turnover Markers Compared to Oral Risedronate Over 1 Year in Patients with Glucocorticoid‐Induced Osteoporosis (2009) (0)
Acute Biological Effects of An Oral Calcitonin Analog in Pagets-disease (1993) (0)
Effect of Single Annual Infusion of Zoledronic Acid (5 Mg) On Lumbar Spine Bone Mineral Density Versus Daily Oral Risedronate (5 Mg) in Subgroups of Patients Receiving Glucocorticoid Therapy (2009) (0)
Total leukocyte and neutrophil counts in patients with anorexia nervosa are correlated with body fat mass values. (1995) (0)
Eighth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis–ECCEO 8 (2008) (0)
The simple calculates osteoporosis risk estimation (score) tool is more useful to reduce densitometry costs than for selecting patient with high risk of osteoporosis (2000) (0)
Preliminary results on intravenous pamidronate in children suffering from osteogenesis imperfecta (2000) (0)
Action of sandoz salmon calcitonin on the urinary pyridinium crosslinks excretion in patients with Paget's disease (1992) (0)
Do new methods of investigation allow faster assessment of drugs efficacy in osteoarthritis (2003) (0)
Evaluation of a screenings program for postmenopausal osteoporosis in primary care setting in Belgium (2002) (0)
Failure of ipriflavone to significantly reduce vertebral fracture rates and to increase bone mineral density in postmenopausal osteoporosis : the IMEFS study (2000) (0)
Effect of Single Annual Infusion of Zoledronic Acid On Bone Turnover Markers Versus Daily Oral Risedronate in Patients With Glucocorticoid-induced Osteoporosis (2009) (0)
Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients (2005) (0)
Systemic Manifestations of Rheumatoid Polyarthritis (1982) (0)
The examination of age and sex-related changes in trabecular architecture in archaeological skeletons with pQCT. (2003) (0)
Strontium ranelate increases the number of patients with improvement in osteoarthritis symptoms compared to placebo in the SEKOIA study (2013) (0)
Characteristics of early Paget's disease in SQSTMI mutation carriers: baseline analysis of the ZIPP study cohort. Bone and Mineral Research. (2020) (0)
among Belgian Postmenopausal Women with Outdoor Activities during Summer Urban Tropospheric Ozone Increases the Prevalence of Vitamin D Deficiency (2008) (0)
Axonal polyneuropathy without vasculitis, follicular lymphoma and primitive sicca syndrome. A rare association (1990) (0)
Precision of DXA BMD measurements in the rat (2006) (0)
Cumulative and sustained efficacy of raloxifene on the risk of new vertebral fractures after 4 years of treatment in postmenopausal women with osteoporosis (2001) (0)
Oral pamidronate prevents lumbar spine bone loss in premenopausal female patients suffering from connective tissue disease treated with high doses of glucocorticoids (2003) (0)

This paper list is powered by the following services:

Jean‐pierre Devogelaer's Academic­Influence.com Rankings

Jean‐pierre Devogelaer's Degrees

Why Is Jean‐pierre Devogelaer Influential?

Jean‐pierre Devogelaer's Published Works

Published Works

Jean‐pierre Devogelaer's AcademicInfluence.com Rankings